Kyowa Kirin Overview
- Year Founded
-
1949
- Status
-
Public
- Employees
-
3,503
- Stock Symbol
-
4151
- Investments
-
13
- Share Price
-
$15.93
- (As of Friday Closing)
Kyowa Kirin General Information
Description
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
Contact Information
Website
www.kyowakirin.co.jp/index.htmlCorporate Office
- Otemachi Financial City Grand Cube
- 1-9-2 Otemachi, Chiyoda-ku
- Tokyo, 100-0004
- Japan
Corporate Office
- Otemachi Financial City Grand Cube
- 1-9-2 Otemachi, Chiyoda-ku
- Tokyo, 100-0004
- Japan
Kyowa Kirin Stock Performance
As of 20-Nov-2026, Kyowa Kirin’s stock price is $15.93. Its current market cap is $8.34B with 524M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.93 | $16.10 | $13.43 - $18.68 | $8.34B | 524M | 1.79M | $1.01 |
Kyowa Kirin Financials Summary
As of 30-Jun-2026, Kyowa Kirin has a trailing 12-month revenue of $3.43B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,986,570 | 7,142,692 | 6,108,979 | 6,459,799 |
| Revenue | 3,431,069 | 3,319,529 | 3,272,126 | 3,147,336 |
| EBITDA | 810,561 | 750,316 | 752,739 | 808,902 |
| Net Income | 526,757 | 447,926 | 395,316 | 577,808 |
| Total Assets | 6,984,068 | 7,082,281 | 6,797,181 | 7,274,637 |
| Total Debt | 168,040 | 198,936 | 183,067 | 171,928 |
Kyowa Kirin Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kyowa Kirin Comparisons
Industry
Financing
Details
Kyowa Kirin Competitors (33)
One of Kyowa Kirin’s 33 competitors is Shionogi, a Corporation company based in Osaka, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Shionogi | Corporation | Osaka, Japan | ||||
| Sumitomo Pharma | Corporation | Osaka, Japan | ||||
| Taiho Pharma | Corporation | Tokyo, Japan | ||||
| Hoechst Pakistan | Corporate Backed or Acquired | Karachi, Pakistan | ||||
| Cipla | Corporation | Mumbai, India |
Kyowa Kirin Patents
Kyowa Kirin Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026177128-A1 | Fusion protein | Pending | 18-Feb-2025 | ||
| WO-2026141571-A1 | Compound with slc15a4 inhibitory activity | Pending | 26-Dec-2024 | ||
| WO-2026084068-A1 | Antibody that binds to human tpor | Pending | 18-Oct-2024 | ||
| WO-2026034490-A1 | Compound having slc15a4 inhibitory activity | Pending | 06-Aug-2024 | ||
| WO-2026020076-A1 | Method for treating prurigo nodularis | Pending | 18-Jul-2024 | C07K16/2878 |
Kyowa Kirin Signals
Kyowa Kirin Investments & Acquisitions (13)
Kyowa Kirin’s most recent deal was a Early Stage VC with Link Cell Therapies for . The deal was made on 28-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Link Cell Therapies | 28-Sep-2026 | Early Stage VC | Drug Discovery | ||
| Stratus Therapeutics | 04-Mar-2025 | Early Stage VC | Drug Discovery | ||
| Orchard Therapeutics | 24-Jan-2024 | Merger/Acquisition | Biotechnology | ||
| Grünenthal Meds | 02-Aug-2023 | Joint Venture | Other Pharmaceuticals and Biotechnology | ||
| Ring Therapeutics | 09-Mar-2023 | Later Stage VC | Drug Discovery |
Kyowa Kirin ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
22.07 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Kyowa Kirin Exits (5)
Kyowa Kirin’s most recent exit was on 04-Mar-2025 from Stratus Therapeutics. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Stratus Therapeutics | 04-Mar-2025 | Completed |
|
||
| Grünenthal Meds | 02-Aug-2023 | Completed |
|
||
| Ardelyx | 25-Nov-2019 | Completed |
|
||
| TargaZyme | 01-Jan-2017 | Completed |
|
||
| Mohan Medicine Research Institute Company | 01-Jan-1990 | Merger/Acquisition | Completed |
Kyowa Kirin Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Kyowa Kirin Frontier Kk | Tokyo, Japan | 2017 | |
| Kyowa Kirin International | Galashiels, United Kingdom | 1995 | |
| Kyowa Hakko Kirin Korea | Seoul, South Korea | 1991 | |
| Kyowa Pharma Chemical | Takaoka City, Japan | 1946 | |
| Kyowa Kirin Plus Co. | Tokyo, Japan |
Kyowa Kirin FAQs
-
When was Kyowa Kirin founded?
Kyowa Kirin was founded in 1949.
-
Where is Kyowa Kirin headquartered?
Kyowa Kirin is headquartered in Tokyo, Japan.
-
What is the size of Kyowa Kirin?
Kyowa Kirin has 3,503 total employees.
-
What industry is Kyowa Kirin in?
Kyowa Kirin’s primary industry is Drug Discovery.
-
Is Kyowa Kirin a private or public company?
Kyowa Kirin is a Public company.
-
What is Kyowa Kirin’s stock symbol?
The ticker symbol for Kyowa Kirin is 4151.
-
What is the current stock price of Kyowa Kirin?
As of 20-Nov-2026 the stock price of Kyowa Kirin is $15.93.
-
What is the current market cap of Kyowa Kirin?
The current market capitalization of Kyowa Kirin is $8.34B.
-
What is Kyowa Kirin’s current revenue?
The trailing twelve month revenue for Kyowa Kirin is $3.43B.
-
Who are Kyowa Kirin’s competitors?
Shionogi, Sumitomo Pharma, Taiho Pharma, Hoechst Pakistan, and Cipla are some of the 33 competitors of Kyowa Kirin.
-
What is Kyowa Kirin’s annual earnings per share (EPS)?
Kyowa Kirin’s EPS for 12 months was $1.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process